上海上药交联医药科技

SPH Cross-linked is a specialized biotechnology company focused on the discovery and development of next-generation antibody-drug conjugates (ADCs). As a key R&D subsidiary of Shanghai Pharma, the company leverages proprietary linker and conjugation platforms to create targeted oncology therapeutics. Its lead clinical candidate, SRD4410, is an ADC targeting Claudin 18.2, currently being evaluated in Phase 1 trials for advanced solid tumors. The company integrates antibody engineering with advanced chemical synthesis to optimize the therapeutic index of its pipeline candidates. SPH Cross-linked plays a central role in Shanghai Pharma's strategy to expand its footprint in the global biologics and precision medicine market.